TuHURA Biosciences SEC Filings

TuHURA Biosciences (HURA) filed a mixed Form S-3 registering up to $250,000,000 of securities and a concurrent resale of up to 9,321,545 shares of common stock by selling stockholders, including 4,570,629 outstanding shares and up to 4,750,916 shares issuable upon warrant exercise. The filing also includes an ATM prospectus supplement permitting sales of up to $50,000,000 of common stock under a Sales Agreement, which is part of the $250,000,000 base shelf.

The company may offer debt, equity, warrants, subscription rights, units, and purchase contracts from time to time, with terms to be set in future supplements. TuHURA states it will not receive proceeds from selling stockholder resales. Unless otherwise described in a supplement, net proceeds from primary issuances are intended for working capital and general corporate purposes. HURA trades on Nasdaq; the last reported price was $2.48 on October 30, 2025.

TuHURA Biosciences, Inc. filed an 8-K to provide updates on its business and operations and to refresh risk disclosures. Under Item 8.01, the company furnished Exhibit 99.1 (business updates) and Exhibit 99.2 (updated risk factors) that supplement prior 10-K and 10-Q disclosures.

Under Item 9.01, TuHURA also included Exhibit 99.3, unaudited pro forma condensed combined financial information, presented as of and for the period ended June 29, 2025 and for the year ended December 31, 2024. The filing also contains forward-looking statements language.

TuHURA Biosciences filed a prospectus supplement for the proposed resale by selling stockholders of up to 4,570,629 shares of common stock and up to 4,750,916 shares issuable upon exercise of warrants. The supplement incorporates a new Current Report on Form 8‑K and must be read with the base prospectus. TuHURA’s common stock trades on Nasdaq as HURA; the last reported sale price on October 30, 2025 was $2.48 per share.

The attached 8‑K discloses a secured bridge loan facility of up to $3,000,000 entered on October 27, 2025. An initial $1,500,000 advance was funded, with an additional $1,500,000 available during a 30‑day period. The loan bears 3% per month interest, maturing on December 31, 2025 or 30 days after an equity financing with gross cash proceeds over $12,000,000. It is secured by a first‑priority perfected security interest in U.S. patents related to ImmuneFx. In connection with the initial advance, the lender received a warrant to purchase 65,217 shares at the Nasdaq Official Closing Price on the grant date; each such warrant is immediately exercisable and expires two years from issuance.

TuHURA Biosciences (HURA) entered a secured bridge loan facility of up to $3,000,000, with an initial $1,500,000 advance, to fund working capital. The loan bears interest at 3% per month and is due on the earlier of December 31, 2025 or 30 days after closing an equity financing with gross cash proceeds exceeding $12,000,000. A $180,000 loan fee is payable at maturity, and prepayment is allowed without penalty.

The facility is secured by a first priority perfected security interest in U.S. patents related to TuHURA’s ImmuneFx technology platform. In connection with each advance, the lender receives warrants equal to 10% of the loan amount divided by the exercise price set at the Nasdaq Official Closing price on the grant date. On the initial advance date, TuHURA issued a warrant to purchase up to 65,217 shares, immediately exercisable and expiring two years from issuance.

TuHURA Biosciences' amended S-1 (S-1/A) describes a clinical-stage biopharma focused on innate and tumor microenvironment immunotherapies. The filing notes initiation of a Phase 3 trial of IFx-2.0 in June 2025 using the FDA accelerated approval pathway and reports prior early-stage data: 23 patients enrolled in an IFx-2.0 study with no grade 3+ toxicities, a recommended Phase 2 dose, a 48% disease control rate at injected lesions at 28 days and a post-protocol objective response rate of 64% (7 of 11) in Merkel cell carcinoma after ICI rechallenge. TuHURA acquired Kineta assets including TBS-2025 (VISTA antibody) in June 2025 and plans a randomized Phase 2 in mutNPM1 AML (menin inhibitor ± TBS-2025) to start in late Q4 2025. Financial disclosures state the company has no product revenue, substantial operating losses, a going concern qualification and material non-cash charges (~$16.9M, including a $16.2M IPR&D write-off). The S-1/A also details a prior merger transaction structure and executive employment and compensation terms.